Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Diabetes
•
Gastroenterology
•
Neurology
•
Autonomic Neurology
•
Endocrinology
•
Neuro-Gastroenterology
•
Gastrointestinal Functional & Motility Disorders
Do 5HT4 agonists such as Metoclopramide actually lead to improvement in symptoms for patients with diabetes related gastroparesis?
Related Questions
How do you counsel patients on the use of compounded weight loss medications?
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
Is there a role for use of GLP1 R agonist or dual agonist therapy for management of post bariatric hypoglycemia and dumping syndrome?
What is the optimal BP target for patients with diabetes and hypertension to reduce their risk of MI/stroke?
Should we be using body fat percentage instead of BMI for determining patients' risk of metabolic syndrome?
Would you recommend statin initiation in a young adult patient (age < 40) with type 1 diabetes mellitus and LDL cholesterol levels greater than 100 without any cardiovascular risk factors?
After what time frame off GLP-1 RA therapy should you restart at the lowest starting dose?
How do you adjust your HbA1c goal for managing diabetes in elderly patients with multiple chronic illnesses but no limitations in performing self-care tasks?
How do you counsel patients who experience diarrhea from mycophenolate mofetil (Cellcept)?
How do the results of the ESPRIT trial, which evaluated the impact of an SBP target of <120 mmHg on preventing major cardiovascular events, influence your blood pressure management goals for hypertensive patients with diabetes or a history of stroke?
